transapical delivery, currently finalizing preclinical regulatory studies and planned to enter human use the first half of next year. A trans-septal system is also in development and will enter human studies following transapical validation. The Saturn prosthesis consists of a mitral bovine bioprosthesis assembled onto a Nitinol self-expanding stent. Saturn's unique anchoring and sealing structure design allows the clinician to accurately deliver the prosthesis in the anatomically correct position thus ensuring a precise alignment within the patient's native valve. The proprietary single part, multi-functional system provides active fixation and resistance to migration. The system's sub-annular ring affords inverse remodelling of the mitral annulus and the low profile of the prosthesis ensures unimpeded flow from the left ventricle after implantation.
About InnovHeart
Ad Statistics
Times Displayed: 2548
Times Visited: 12 Fast-moving cardiac structures have a big impact on imaging. Fujifilm’s SCENARIA View premium performance CT brings solutions to address motion in Coronary CTA while delivering unique dose saving and workflow increasing benefits.
InnovHeart s.r.l., domiciled in Milan (Italy) with operations in Ivrea (Italy) and Poway, Calif. (USA), develops transcatheter mitral valve replacement (TMVR) systems to treat patients suffering from mitral valve disease. The Company is in late preclinical development of its novel TMVR Saturn Prosthesis, designed for trans-apical delivery. A transseptal Saturn system is being developed to follow the transapical clinical validation. InnovHeart is backed by leading investor Genextra S.p.A, Italian holding company specialized in early-stage investments in the life sciences sector.
SOURCE InnovHeart s.r.l.
Back to HCB News
